Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 18/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994306 | 0.98 | SSTR4 (0.44) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL4343351 | 0.84 | SSTR4 (0.41) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL13738797 | 0.77 | SSTR4 (0.41) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL22513280 | 0.77 | SSTR4 (0.46) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL20565286 | 0.77 | SSTR4 (0.47) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL31170845 | 0.77 | HTR2C (0.48) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL19582237 | 0.77 | CD44 (0.51) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Trifluoroacetic Acid SCHEMBL3277737 | 0.74 | SSTR4 (0.43) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Hydrochloric Acid SCHEMBL3276373 | 0.74 | SSTR4 (0.54) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL2052908 | 0.74 | PARP1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222669-B1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8222245-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2222669-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | Glaxo Group Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100174065-A1 | COMPOUNDS | GLAXO GROUP LIMITED (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2009080725-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174065-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | SSTR4 2703/4885SSTR1 3400/4885SSTR2 2070/4885 |
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | S1PR3, S1PR1, S1PR2 | SSTR4 1058/4885SSTR1 876/4885SSTR2 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.